Please login to the form below
atopic dermatitis
This page shows the latest atopic dermatitis news and features for those working in and with pharma, biotech and healthcare.
Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
Around 80, 000 infants and young children in Europe are living with uncontrolled cases of atopic dermatitis, a chronic type 2 inflammatory skin disease. ... Given its well-established safety and efficacy profile, Dupixent has the potential to transform
Latest news
-
Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
Typically referred to as eczema, atopic dermatitis is one of the most common inflammatory skin diseases, affecting over 26 million people in the US alone. ... Dupixent has already received regulatory approvals for use in certain patients with atopic
-
Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
More commonly referred to as eczema, atopic dermatitis is one of the most common inflammatory skin diseases, affecting over 26 million people in the US alone and up to 10% of ... treatment option for atopic dermatitis patients, including children as
-
Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
Atopic dermatitis is a chronic type 2 inflammatory skin disease. Between 85% and 90% of patients first develop symptoms before the age of five, often continuing throughout adulthood. ... The medicine was approved by the US Food and Drug Administration in
-
Sanofi/ Regeneron’s Dupixent recommended by CHMP to treat eosinophilic oesophagitis
To date, the treatment has received regulatory approvals in one or more countries around the world for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, EoE
-
MHRA approves LEO Pharma’s Adtralza for adolescent patients with atopic dermatitis
patients, aged 12 years and older, with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. ... To date, tralokinumab is also approved for the treatment of adults with moderate-to-severe atopic dermatitis in Canada, the
More from news
Approximately 23 fully matching, plus 91 partially matching documents found.
Latest Intelligence
-
How AI is finally helping rare diseases gain more than just attention
That’s the approach companies like BenevolentAI have taken. Its treatment for atopic dermatitis is now in phase 2 clinical trials and was discovered using machine learning technology.
-
20 for 2020 – Five pharma leaders to watch in 2020
pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia.
-
Case study: See Below
We needed to pique delegates’ interest and show them a new approach to treating atopic dermatitis. ... But, how? Before diving head-first into the idea, we enlisted the help of key stakeholders within atopic dermatitis.
-
Innovation and digital health comms recognised at Communiqué Awards
The video played while the lift whisked its passengers into the congress, creating a six-minute video ‘experience’ which challenged dermatologists to change the way they treated atopic dermatitis. ... In order to target their message, the creative
-
Drug launches to watch in 2019
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... Likewise, upadacitinib will face competition in both RA and atopic dermatitis,
More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.
Latest appointments
-
Dr Desiree Luthman joins Verona Pharma
atopic dermatitis in the US.
-
Ziarco appoints Mike Grey to board of directors
Concerning his appointment, Grey said: “I am delighted to join Ziarco's board, as the company has a strong leadership team and promising lead compounds for the treatment of atopic dermatitis
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas
Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies
-
Fishawack Health welcomes expert-led dermatology initiative FIDE to its group
Biopharmaceutical companies are increasingly focusing their attention on developing treatments for these dermatological conditions, with more than 80 products in development to treat atopic dermatitis and psoriasis. ... About FIDE. FIDE is a full-service
-
Rethinking immunodermatology: Patient and market insights from leading KOLs and life science leaders
Today, there are more than 80 treatments in development for atopic dermatitis and psoriasis.
-
Atopic Dermatitis — Going Beyond the Pill
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
-
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
More from PMHub
Approximately 5 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
